<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253431</url>
  </required_header>
  <id_info>
    <org_study_id>mp08.13</org_study_id>
    <nct_id>NCT04253431</nct_id>
  </id_info>
  <brief_title>The Characteristics of Different Personal Lancets on Blood Volume and Perceived Pain in Patients With Diabetes Mellitus</brief_title>
  <official_title>A Single-blind, Randomized, Single-centre Study to Investigate the Characteristics of Different Personal Lancets on Blood Volume and Perceived Pain in Patients With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HTL-Strefa S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HTL-Strefa S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized single-blind study with the use of different lancing devices equipped with
      personal lancets to determine and to compare the amount of capillary blood volume and
      perceived pain after a single lancing of the fingertip.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume (uL) of blood in the capillary tube</measure>
    <time_frame>The blood from the puncture site was collected to the capillaries for 30 seconds, and afterwards amount of the blood was measured using a calibrated ruler</time_frame>
    <description>Examination of the volume of blood obtained after puncturing a fingertip with the use of different lancing devices set to maximum puncture depth, with the use of various-sized personal lancets (28G and 33G).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The intensity of pain perceived by the patient assessed with the use of the VAS (Visual Analog Scale).</measure>
    <time_frame>3 minutes (+/- 1 minute) after lancing</time_frame>
    <description>Examination of the intensity of pain perceived when puncturing a fingertip with the use of different lancing devices set to maximum puncture depth, with the use of various-sized personal lancets (28G and 33G).</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>L01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Finger pricking using lancing device with personal lancets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Finger pricking using lancing device with personal lancets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L03</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Finger pricking using lancing device with personal lancets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L04</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Finger pricking using lancing device with personal lancets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L05</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Finger pricking using lancing device with personal lancets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L06</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Finger pricking using lancing device with personal lancets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L07</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Finger pricking using lancing device with personal lancets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L08</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Finger pricking using lancing device with personal lancets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L09</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Finger pricking using lancing device with personal lancets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Finger pricking using lancing device with personal lancets</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Droplet lancing device (HTL-Strefa S.A.)</intervention_name>
    <arm_group_label>L01</arm_group_label>
    <arm_group_label>L04</arm_group_label>
    <arm_group_label>L08</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microlet 2 lancing device (Bayer)</intervention_name>
    <arm_group_label>L02</arm_group_label>
    <arm_group_label>L07</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OneTouch Delicia lancing device (LifeScan)</intervention_name>
    <arm_group_label>L03</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReliOn lancing device (ReliOn)</intervention_name>
    <arm_group_label>L05</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Accu-Chek Softclix lancing device (Roche)</intervention_name>
    <arm_group_label>L06</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BGStar lancing device (Sanofi Aventis)</intervention_name>
    <arm_group_label>L09</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultra-Fine 33G lancets (BD)</intervention_name>
    <arm_group_label>L01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Droplet 33G lancets (HTL-Strefa S.A.)</intervention_name>
    <arm_group_label>L02</arm_group_label>
    <arm_group_label>L08</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OneTouch Delicia Extra Fine 33G lancets (LifeScan)</intervention_name>
    <arm_group_label>L03</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HaemoFine 33G lancets (HTL-Strefa S.A.)</intervention_name>
    <arm_group_label>L04</arm_group_label>
    <arm_group_label>L10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Softclix 28 G lancets (Roche)</intervention_name>
    <arm_group_label>L06</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReliOn Ultra-Thin Plus 33G lancets (ReliOn)</intervention_name>
    <arm_group_label>L05</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GlucoJect Dual S lancing device (Menarini)</intervention_name>
    <arm_group_label>L10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microlet 28G lancets (Bayer)</intervention_name>
    <arm_group_label>L07</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BGStar Ultra-Thin 33G lancets (Sanofi Aventis)</intervention_name>
    <arm_group_label>L09</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to sign the informed consent.

          -  Must currently be diagnosed with either Type I or Type II diabetes mellitus.

          -  Otherwise in good physical and mental health.

          -  Must currently be performing self-monitoring of blood glucose (self reported).

          -  Must be between 18-75 years of age (inclusive).

          -  Ability to read and follow study instructions.

        Exclusion Criteria:

          -  Pregnancy (self reported).

          -  Severe poor blood circulation in the fingers.

          -  Any skin condition on his or her fingers that prevents blood sampling.

          -  History of a bleeding disorder.

          -  Neuropathy or other condition affecting sensation in the hands.

          -  Self-reported blood borne infection (e.g., HIV, hepatitis B or C, syphilis, malaria,
             babesiosis, brucellosis, leptospirosis, arboviral infections, relapsing fever, T
             lymphotropic virus Type 1, Creutzfeldt-Jakob disease).

          -  Currently participating in another study.

          -  History of drug or alcohol abuse within the 12 months prior to screening or evidence
             of such abuse.

          -  Donation or loss of 400 mL or more of blood within 4 weeks prior to the start of the
             study.

          -  Any prescription or OTC medication within two days of starting the study which might
             affect pain perception (for example, ibuprofen or paracetamol).

          -  Alcohol 48 hours before study start.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lancing device</keyword>
  <keyword>lancet</keyword>
  <keyword>fingerprick</keyword>
  <keyword>capillary blood</keyword>
  <keyword>self-monitoring of blood glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

